The selective knockout of Atg12 was associated with a strong decrease of tumor cell burden when compared with vehicle treatment, as indicated by the reduced percentage of human leukemic cells (hCD45 + ) in murine bone marrow and the spleen (Fig. 3e, f). This evidence concerns the gene ATG12 and neoplasm.